智通财经APP讯，医渡科技(02158)发布公告，于2026年2月26日斥资228.02万港元回购38.2万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫渡科技有限公司 呈交日期： 2026年2月26日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存 ...

Core Insights - The report highlights changes in the Hong Kong Stock Connect holdings, indicating significant increases and decreases in ownership percentages for various companies. Group 1: Recent Increases in Holdings - VITASOY INT'L (00345) saw an increase of 0.09%, bringing its latest holding percentage to 3.75% [1] - 恒生科技ETF (03032) increased by 0.04%, with a current holding of 18.49% [1] - 永升服务 (01995) experienced a rise of 0.01%, now holding 4.57% [1] - 南方东西精选 (03441) had the largest increase over five days at 18.46%, reaching 41.03% [4] - 喜相逢集团 (02473) increased by 10.04%, with a holding of 45.14% [4] - 兆易创新 (03986) rose by 4.95%, now at 6.65% [4] Group 2: Recent Decreases in Holdings - 南方恒生科技 (03033) experienced the largest decrease of -0.14%, with a current holding of 68.87% [2] - 医渡科技 (02158) decreased by -0.03%, now at 22.59% [2] - 盈富基金 (02800) saw a reduction of -0.02%, with a holding of 3.49% [2] - 山东墨龙 (00568) had a five-day decrease of -1.30%, now at 53.56% [5] - 亿华通 (02402) decreased by -1.00%, with a holding of 27.49% [5] - 国富氢能 (02582) saw a reduction of -0.90%, now at 20.14% [5] Group 3: Long-term Trends in Holdings - Over a 20-day period, 喜相逢集团 (02473) had the highest increase of 42.45%, reaching 45.14% [6] - 南方东西精选 (03441) increased by 27.31%, now at 41.03% [6] - 钧达股份 (02865) rose by 15.74%, with a holding of 64.80% [6] - 天齐锂业 (09696) experienced a significant decrease of -6.48%, now at 31.50% [6] - 金风科技 (02208) decreased by -5.88%, with a holding of 42.49% [6]

Core Insights - Yidu Tech has launched the "Yidu Smart Cycle" clinical evidence AI tool, currently in the internal testing phase, aimed at meeting the real needs of clinical doctors and medical researchers [1][2] - The AI tool is built on a foundation of over 30,000 authoritative sources selected from more than 40,000 guidelines and integrates over 5 million high-quality research outcomes from 30 million documents [1] - The tool has been validated through clinical trials with over 100,000 real clinical cases, achieving decision-making levels close to that of chief physicians [1] Company Developments - The internal testing phase involves frontline doctors with real practice backgrounds to provide feedback for optimizing the product's clinical utility [2] - There are plans to launch an app version to reach a broader audience of doctors [2] - The product aims to address the growing importance of evidence-based medicine in clinical decision-making and seeks to fill a market gap in high-quality clinical evidence AI in China [2]

本报讯 （记者张敏）2月25日，记者获悉，医渡科技有限公司（以下简称"医渡科技"）推出的"医渡智 循"临床循证智能体目前已进入内测阶段，这款小程序专为临床医生与医学研究者打造，聚焦医生临床 诊疗和科研场景的真实需求，正在邀请一线临床医生参与体验与共创。 业内人士指出，当前循证医学在临床决策中的地位日益凸显，"医渡智循"对标OpenEvidence并实现本土 化创新。未来若能切实贴合中国医生的工作流程、更紧密融入临床数据并解决真实临床痛点，该产品将 有望跑通可持续的商业模式，有效填补国内高质量临床循证AI领域的市场空白。 据了解，"医渡智循"的核心优势在于构建了"丰富真实的权威数据基石"与"深度理解临床意图的AI引 擎"：一方面，该智能体从超4万份指南中精选超3万份权威来源，从超3000万份文献中精选超500万份高 质量科研成果，并整合权威医学知识库；另一方面，该智能体通过创新医学语言处理与建模、智能精排 与反馈式推理、多维意图理解与PICO拆解等技术，将医疗文档转化为可计算的原子知识，精准识别临 床需求并指向循证依据，同时限制AI幻觉，确保决策参考的可靠性。 目前，"医渡智循"已率先通过中山大学肿瘤防治中心等 ...

另据可靠消息，医渡科技临床循证智能体"医渡智循"已开启内测。据了解，该产品专为临床医生与医学 研究者打造，聚焦临床诊疗和科研场景的真实需求，本次内测邀请具备真实执业背景的一线医生参与， 通过真实执业场景的反馈进一步优化产品临床实用性。此前其打造的"医生Copilot"在单院实现日均被调 用近千次，覆盖了约70%的临床医护人员，成为医生诊疗全程的得力伙伴，"医渡智循"的推出进一步丰 富了其智能体产品矩阵。 当前AI医疗行业政策与技术双轮驱动，国家八部门联合印发的《"人工智能+医疗卫生"应用发展实施意 见》中明确2030年实现二级以上医院智能辅助诊断全覆盖，临床循证类工具成为行业刚需。医渡科技一 边以持续回购传递价值认可，一边加速产品创新落地，其在AI医疗赛道的竞争力持续夯实，长期发展 值得期待。 智通财经APP获悉，2月24日，医渡科技(02158)发布最新股份回购公告：公司当日以每股约5.96港元的 价格回购72万股，总耗资近430万港元，延续2026年以来的密集回购节奏。自1月26日以来，公司已完成 17次回购，累计斥资超7200万港元，以持续的资本动作彰显对自身发展及行业前景的双重信心。 ...

Core Viewpoint - The company, Yidu Tech (02158), demonstrates confidence in its development and industry prospects through continuous share buybacks and product innovation in the AI healthcare sector [1]. Group 1: Share Buyback Activity - On February 24, Yidu Tech announced a share buyback of 720,000 shares at approximately HKD 5.96 per share, totaling nearly HKD 4.3 million [1]. - Since January 26, the company has completed 17 buybacks, with a cumulative expenditure exceeding HKD 72 million, reflecting a strong commitment to shareholder value [1]. Group 2: Product Development - Yidu Tech's clinical evidence-based AI tool, "Yidu Zhixun," has entered internal testing, aimed at clinical doctors and medical researchers, focusing on real-world clinical and research needs [1]. - The internal testing involves frontline doctors with real practice backgrounds to optimize the product's clinical usability based on actual feedback [1]. - The previously developed "Doctor Copilot" tool has been utilized nearly 1,000 times daily in a single hospital, covering about 70% of clinical healthcare personnel, indicating strong product adoption [1]. Group 3: Industry Context - The AI healthcare industry is driven by both policy and technology, with a joint issuance from eight national departments outlining plans for full coverage of intelligent diagnostic assistance in secondary hospitals by 2030 [1]. - Clinical evidence-based tools are becoming essential in the industry, positioning Yidu Tech favorably as it continues to innovate and reinforce its competitive edge in the AI healthcare sector [1].

格隆汇2月24日丨医渡科技(02158.HK)公告，2月24日耗资428.9万港元回购72万股。 ...

智通财经APP讯，医渡科技(02158)发布公告，于2026年2月24日斥资428.9万港元回购72万股。 ...

医渡科技(02158)发布公告，于2026年2月24日斥资428.9万港元回购72万股。 ...